

**PATENT ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
Technion Research and Development Foundation, Ltd.	06/27/2011
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	Teva Pharmaceutical Industries, Ltd.
<b>Street Address:</b>	5 Basel Street
<b>Internal Address:</b>	P.O. Box 3190
<b>City:</b>	Petach-Tikva
<b>State/Country:</b>	ISRAEL
<b>Postal Code:</b>	49131
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Patent Number:</b>	5744500
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(212)391-0525
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
<b>Phone:</b>	212-278-0400
<b>Email:</b>	mli@cooperdunham.com
<b>Correspondent Name:</b>	Cooper & Dunham LLP
<b>Address Line 1:</b>	30 Rockefeller Plaza
<b>Address Line 4:</b>	New York, NEW YORK 10112
<b>NAME OF SUBMITTER:</b>	Michael Lin
<b>Total Attachments: 5</b> source=110812_2609_43017_Signed_Assignment_Page1_ML#page1.tif source=110812_2609_43017_Signed_Assignment_Page2_ML#page1.tif source=110812_2609_43017_Signed_Assignment_Page3_ML#page1.tif source=110812_2609_43017_Signed_Assignment_Page4_ML#page1.tif source=110812_2609_43017_Signed_Assignment_Page5_ML#page1.tif	

**CH \$40.00 5744500**

## PATENT RIGHTS ASSIGNMENT

This Patent Rights Assignment (this "Assignment") is made effective October 1, 2010, by and between the Technion Research & Development Foundation, Ltd., ("Assignor"), and Teva Pharmaceutical Industries Ltd. ("Assignee").

WHEREAS, Assignor possesses certain rights in and to the Patent Applications and Patents set forth in Schedule A and Supplementary Protection Certificates (SPCs) set forth in Schedule B, each attached hereto and incorporated herein by reference (collectively, the "Assigned Patents"); and

WHEREAS, Assignor now wishes to assign all of its right, title and interest in and to the Assigned Patents to Assignee, and Assignee desires to acquire all of Assignor's right, title and interest in and to the Assigned Patents from Assignor;

NOW, THEREFORE, in consideration of Ten Thousand Dollars (10,000 USD) and for other good and valid consideration (including the costs of recordation of assignment), the receipt and sufficiency of which is hereby acknowledged:





Assignor does hereby assign, convey and transfer unto Assignee and its successors, assigns, and legal representatives, Assignor's entire right, title and interest in and to the Assigned Patents (including any and all patent term extensions, reissues, reexaminations, extensions or supplementations thereof, and every priority right) to the full end of the term for which said rights have been granted as fully and entirely as the same would have been held by Assignor had this assignment not been made; and Assignor hereby conveys all of its rights in and to the Assigned Patents arising under or pursuant to any and all laws relating to the protection of patent rights, including but not limited to any cause(s) of action and damages accruing prior to this Assignment.

Assignor hereby further agrees for itself and its successors, assigns, agents, and legal representatives to execute upon request any other lawful documents and likewise to perform any other lawful acts which may be deemed necessary to secure fully the rights in the Assigned Patents to Assignee, its successors, assigns, and legal representatives, and generally do everything possible to aid Assignee, its successors, assigns and legal representatives to obtain, record, maintain, and enforce full protection for the Assigned Patents in all countries, but in each instance at Assignee's expense.

Assignor hereby warrants that it has not conveyed to anyone other than Assignee any rights in the Assigned Patents or any license to use the same or to make, use or sell anything embodying or utilizing any of the Assigned Patents, and that it has good right to assign the Assigned Patents to Assignee without encumbrance.

Assignor does hereby authorize all proper governmental authorities to record this Assignment of the Assigned Patents to show that all right, title and interest in the Assigned Patents reside with the Assignee, its successors, assigns, or legal representatives in accordance with the terms of this Assignment.

IN WITNESS WHEREOF, Assignor has caused this Assignment to be executed by its duly authorized representative as of the date first written above.

Technion Research and Development Foundation Ltd. (Assignor)  
Technion Research and Development Foundation Ltd.  
By: Oded Shmueli  By: Benjamin Soffer   
Printed Name: ODED SHMUELI Technion City-Haifa 32000, Israel Printed Name: BENJAMIN SOFFER  
Title: MANAGING DIRECTOR Tel: 04-8325375 Title: MANAGER  
Date: June 27, 2011 Date: June 27, 2011  
Witness:  [signature] Witness:  [signature]  
ALFRED DOUGLAS [printed name] ALFRED DOUGLAS [printed name]  
TECHNION CITY [address] TECHNION CITY [address]  
SENATE BLDG. SENATE BLDG.  
HAIFA 32000 ISRAEL HAIFA 32000 ISRAEL

Teva Pharmaceutical Industries Ltd. (Assignee) hereby accepts this assignment.

By: \_\_\_\_\_ By: \_\_\_\_\_  
Printed Name: \_\_\_\_\_ Printed Name: \_\_\_\_\_  
Title: \_\_\_\_\_ Title: \_\_\_\_\_  
Date: \_\_\_\_\_ Date: \_\_\_\_\_  
Witness: \_\_\_\_\_ Witness: \_\_\_\_\_  
\_\_\_\_\_ [signature] \_\_\_\_\_ [signature]  
\_\_\_\_\_ [printed name] \_\_\_\_\_ [printed name]  
\_\_\_\_\_ [address] \_\_\_\_\_ [address]  
\_\_\_\_\_

IN WITNESS WHEREOF, Assignor has caused this Assignment to be executed by its duly authorized representative as of the date first written above.

**Technion Research and Development Foundation Ltd. (Assignor)**

By: \_\_\_\_\_  
Printed Name: \_\_\_\_\_  
Title: \_\_\_\_\_  
Date: \_\_\_\_\_  
Witness: \_\_\_\_\_  
\_\_\_\_\_ [signature]  
\_\_\_\_\_ [printed name]  
\_\_\_\_\_ [address]  
\_\_\_\_\_

By: \_\_\_\_\_  
Printed Name: \_\_\_\_\_  
Title: \_\_\_\_\_  
Date: \_\_\_\_\_  
Witness: \_\_\_\_\_  
\_\_\_\_\_ [signature]  
\_\_\_\_\_ [printed name]  
\_\_\_\_\_ [address]  
\_\_\_\_\_

**Teva Pharmaceutical Industries Ltd. (Assignee) hereby accepts this assignment.**

By: *Rinat*  
Printed Name: **Rinat Shiran-Rasky**  
Title: **General Patent Counsel**  
Date: June 22, 2011  
Witness: *Vivian Saha* [signature]  
VIVIAN SAHA [printed name]  
5 Basel St [address]  
Petach Tikva  
Israel

By: *P. Hausdorf*  
Printed Name: **Sharon Hausdorf, Ph.D.**  
Title: **Associate General Patent Counsel**  
Date: June 22, 2011  
Witness: *Vivian Saha* [signature]  
Vivian Saha [printed name]  
5 Basel St. [address]  
Petach Tikva  
Israel

**Schedule A (Patent Applications and Patents)**  
to Assignment from Technion Research and Development Foundation Ltd.  
to Teva Pharmaceutical Industries Ltd.

Country	Application/Patent No.	Filing/Grant Date
US	5,668,181	September 16, 1997
US	5,576,353	November 19, 1996
US	5,599,991	February 4, 1997
US	5,891,923	April 6, 1999
US	5,519,061	May 21, 1996
US	5,744,500	April 28, 1998
US	6,316,504	November 13, 2001
US	6,630,514	October 7, 2003
US	6,956,060	October 18, 2005
Australia	630772	February 26, 1993
Austria	0436492	June 8, 1994
Austria	812190	December 8, 2004
Belgium	0436492	June 8, 1994
Belgium	812190	December 8, 2004
Brazil	PI0504448-0	October 24, 2005
Canada	2,031,714	August 25, 1998
Canada	2,174,449	January 16, 2007
Czech Republic	288222	March 13, 2001
Denmark	0436492	June 8, 1994
Denmark	812190	December 8, 2004
Europe	0436492	June 8, 1994
Europe	812190	December 8, 2004
France	0436492	June 8, 1994
France	812190	December 8, 2004
Germany	69102288.7	June 8, 1994
Germany	69434178.9	December 8, 2004
Greece	0436492	June 8, 1994
Greece	3052691	December 8, 2004
Hong Kong	1008017	June 8, 1994
Hungary	215.451	September 6, 2000
Hungary	226.138	April 3, 2008
Ireland	062371	January 9, 1995
Ireland	812190	December 8, 2004
Italy	0436492	June 8, 1994
Italy	812190	December 8, 2004
Japan	2987453	October 8, 1999
Japan	2009-219662	September 24, 2009
Luxembourg	0436492	June 8, 1994
Luxembourg	0 812 190	December 12, 2004
Mexico	236132	April 24, 2006
Monaco	812190	December 8, 2004
Netherlands	0436492	June 8, 1994
Netherlands	812190	December 8, 2004
Portugal	812190	December 8, 2004
Romania	107552	December 20, 1993
Russian Federation	2001614	October 30, 1993
Slovak	280,742	April 6, 2000
South Africa	90/9997	October 30, 1991
South Africa	94/8013	July 26, 1995
Spain	2057604	June 8, 1994
Spain	2235170	December 8, 2004
Sweden	0436492	June 8, 1994
Sweden	812190	December 8, 2004
Switzerland	812190	December 8, 2004
United Kingdom	0436492	June 8, 1994
United Kingdom	812190	December 8, 2004

**Schedule B** (Supplementary Protection Certificates)  
to Assignment from Technion Research and Development Foundation Ltd.  
to Teva Pharmaceutical Industries Ltd.

Country	SPC No.	Grant Date
Austria	31/2005	April 02, 2007
Belgium	2005C/031	September 1, 2009
Czech Republic	28822/82	August 26, 2005
Denmark	CR 2005 00039	February 11, 2008
France	FR05C0033	August 9, 2005
Germany	12 2005 000 044.2	June 25, 2007
Greece	8000193	N/A
Hungary	S000067	November 20, 2008
Ireland	2005/024	August 23, 2006
Italy	895	October 10, 2005
Luxembourg	91 191	October 10, 2005
Netherlands	300205	January 13, 2006
Portugal	CCP 207	N/A
Romania	c2007 035	N/A
Slovak	DO 32	February 24, 2006
Spain	200500037	N/A
Sweden	0590028-7	July 11, 2006
Switzerland	C00812190/01	August 31, 2007
United Kingdom	SPC/GB05/042	June 12, 2007